Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Rovira, Montserrat  [Clear All Filters]
2013
Tovar N, de Larrea CFernández, Aróstegui JI, Cibeira MTeresa, Rosiñol L, Rovira M, Elena M, Filella X, Yagüe J, Bladé J. Natural history and prognostic impact of oligoclonal humoral response in patients with multiple myeloma after autologous stem-cell transplantation: long-term results from a single institution. Haematologica. 2013.
2014
Fehér C, Rovira M, Soriano A, Esteve J, Martínez JAntonio, Marco F, Carreras E, Martínez C, Fernández-Avilés F, Suárez-Lledó M, et al. Effect of meropenem administration in extended infusion on the clinical outcome of febrile neutropenia: a retrospective observational study. J Antimicrob Chemother. 2014.
Vallejo C, Batlle M, Vázquez L, Solano C, Sampol A, Duarte R, Hernandez D, Lopez J, Rovira M, Jimenez S, et al. Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation. Haematologica. 2014.
2015
Hawkey CJ, Allez M, Clark MM, Labopin M, Lindsay JO, Ricart E, Rogler G, Rovira M, Satsangi J, Danese S, et al. Autologous Hematopoetic Stem Cell Transplantation for Refractory Crohn Disease: A Randomized Clinical Trial. JAMA. 2015;314(23):2524-2534.
2018
Corraliza AM, Ricart E, López-García A, Masamunt MCarme, Veny M, Esteller M, Mayorgas A, Le Bourhis L, Allez M, Planell N, et al. Differences in peripheral and tissue immune cell populations following hematopoietic stem cell transplantation in Crohn's disease patients. J Crohns Colitis. 2018.
2019
Gutiérrez-García G, Cibeira MTeresa, Rovira M, de Larrea CFernández, Tovar N, Rodríguez-Lobato LGerardo, Rosiñol L, Marín P, Solano-Vega J, Suárez-Lledó M, et al. Improving security of autologous hematopoietic stem cell transplant in patients with light-chain amyloidosis. Bone Marrow Transplant. 2019.
Suárez-Lledó M, Marcos MAÁngeles, Cuatrecasas M, Bombi JAntoni, Fernández-Avilés F, Magnano L, Martínez-Cibrián N, Llobet N, Rosiñol L, Gutiérrez-García G, et al. Quantitative PCR is faster, more objective and more reliable than immunohistochemistry for the diagnosis of Cytomegalovirus Gastrointestinal disease in allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2019.
2020
de Morales JGRuiz, Cordero-Coma M, Rovira M, Calleja-Antolin S, Espinosa G, Heras Nde Las. Autologous Hematopoietic Stem Cell Transplantation for Susac Syndrome. Ann Intern Med. 2020.
Rodríguez-Lobato L-G, Martínez-Roca A, Castaño-Díez S, Palomino-Mosquera A, Gutiérrez-García G, Pedraza A, Suárez-Lledó M, Rovira M, Martínez C, de Larrea CFernández, et al. The avoidance of G-CSF and the addition of prophylactic corticosteroids after autologous stem cell transplantation for multiple myeloma patients appeal for the at-home setting to reduce readmission for neutropenic fever. PLoS One. 2020;15(11):e0241778.
Peric Z, Labopin M, Peczynski C, Polge E, Cornelissen J, Carpenter B, Potter M, Malladi R, Byrne J, Schouten H, et al. Comparison of reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia >45 years undergoing allogeneic stem cell transplantation-a retrospective study by the Acute Leukemia Working Party of EBMT. Bone Marrow Transplant. 2020.
Berro M, Chhabra S, Piñana JLuis, Arbelbide J, Rivas MM, Basquiera ALisa, Vitriu A, Requejo A, Milovic V, Yantorno S, et al. Predicting mortality after autologous transplant: Development of a novel risk score. Biol Blood Marrow Transplant. 2020.
Ruggeri A, Labopin M, Battipaglia G, Chiusolo P, Tischer J, Diez-Martin JLuiz, Bruno B, Castagna L, Moiseev ISergeevich, Vitek A, et al. The timing of post-transplant cyclophosphamide administration in haploidentical transplantation: a comparative study on behalf of the ALWP of the EBMT. Biol Blood Marrow Transplant. 2020.
2021
Bravo MSantos, Plault N, Palomino SSánchez, Gutierrez MMar Mosque, Avilés FFernández, Lledo MSuarez, Fernández NSabé, Rovira M, Alain S, M Maeso ÁMarcos. Phenotype and genotype study of novel C480F maribavir-ganciclovir cross-resistance mutation detected in hematopoietic stem cell and solid organ transplanted patients. J Infect Dis. 2021.
Sahebi F, Eikema D-J, Koster L, Kröger N, Meijer E, van Doesum JA, Rovira M, Koc Y, Angelucci E, Blaise D, et al. Post-Transplant Cyclophosphamide for Graft vs Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type: A Study from the Chronic Malignancies Working Party of the EBM. Transplant Cell Ther. 2021.
2022
Ruggeri A, Galimard J-E, Labopin M, Rafii H, Blaise D, Ciceri F, Diez-Martin J-L, Cornelissen J, Chevallier P, Sanchez-Guijo F, et al. Comparison of outcomes after unrelated double-unit cord blood and haploidentical peripheral blood stem cell transplantation in adults with acute myeloid leukemia, a study on behalf of Eurocord and ALWP-EBMT. Transplant Cell Ther. 2022.
Salas MQueralt, Charry P, Pedraza A, Martínez-Cibrián N, Solano MTeresa, Domenech A, Suárez-Lledó M, Nomdedeu M, Cid J, Lozano M, et al. PTCY and Tacrolimus for GVHD Prevention for Older Adults Undergoing HLA-Matched Sibling and Unrelated Donor AlloHCT. Transplant Cell Ther. 2022.
2023
Ruiz-Boy S, Pedraza A, Prat M, Salas MQueralt, Carcelero E, Riu-Viladoms G, Suárez-Lledó M, Monge-Escartín I, Rodríguez-Lobato LGerardo, Martínez-Roca A, et al. At-Home Foscarnet Administration in Patients with Cytomegalovirus Infection Post-Allogeneic Stem Cell Transplantation: A Unicentric, Safe, and Feasible Program. Pharmaceuticals (Basel). 2023;16(12).
Pedraza A, Salas MQueralt, Rodríguez-Lobato LGerardo, Escribano-Serrat S, Suárez-Lledó M, Martínez-Cebrian N, Solano MTeresa, Arcarons J, Rosiñol L, Gutiérrez-García G, et al. EASIX SCORE CORRELATES WITH ENDOTHELIAL DYSFUNCTION BIOMARKERS AND PREDICTS RISK OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC TRANSPLANTATION. Transplant Cell Ther. 2023.
Palomo M, Moreno-Castaño ABelén, Salas MQueralt, Escribano-Serrat S, Rovira M, Guillen-Olmos E, Fernández S, Ventosa-Capell H, Youssef L, Crispi F, et al. Endothelial activation and damage as a common pathological substrate in different pathologies and cell therapy complications. Front Med (Lausanne). 2023;10:1285898.
Salas MQueralt, Pedraza A, Charry P, Suárez-Lledó M, Rodríguez-Lobato LGerardo, Brusosa M, Solano MTeresa, Serrahima A, Nomdedeu M, Cid J, et al. Post-transplant Cyclophosphamide and Tacrolimus for GVHD Prevention Allo-HCT from HLA-Matched Donors Generates more Advantages than Limitations. Transplant Cell Ther. 2023.
2024
Greco R, Alexander T, Del Papa N, Müller F, Saccardi R, Sanchez-Guijo F, Schett G, Sharrack B, Snowden JA, Tarte K, et al. Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee. EClinicalMedicine. 2024;69:102476.